{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:10:43Z","timestamp":1760551843853},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s11033-022-08087-5","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T11:10:25Z","timestamp":1670411425000},"page":"1809-1816","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The alternative renin-angiotensin-system (RAS) signalling pathway in prostate cancer and its link to the current COVID-19 pandemic"],"prefix":"10.1007","volume":"50","author":[{"given":"Fabian","family":"Sehn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartwig","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Godau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marten","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Semih","family":"Sarcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Offermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Perner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario W.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie C.","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"issue":"9","key":"8087_CR1","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1097\/00004872-200109000-00012","volume":"19","author":"JR Ballew","year":"2001","unstructured":"Ballew JR, Fink GD (2001) Characterization of the antihypertensive effect of a thiazide diuretic in angiotensin II-induced hypertension. J Hypertens 19(9):1601\u20131606","journal-title":"J Hypertens"},{"issue":"410","key":"8087_CR2","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"MJ Pinter","year":"2017","unstructured":"Pinter MJ, Rakesh K (2017) Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med 9(410):5616","journal-title":"Sci Transl Med"},{"issue":"2","key":"8087_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271-280e8","journal-title":"Cell"},{"issue":"1","key":"8087_CR4","doi-asserted-by":"publisher","first-page":"9110","DOI":"10.1038\/s41598-017-09536-z","volume":"7","author":"Q Wu","year":"2017","unstructured":"Wu Q et al (2017) Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep 7(1):9110","journal-title":"Sci Rep"},{"key":"8087_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3332\/ecancer.2020.1099","volume":"14","author":"A Saha","year":"2020","unstructured":"Saha A, Anirvan P (2020) Cancer progression in COVID-19: integrating the roles of renin angiotensin aldosterone system, angiopoietin-2, heat shock protein-27 and epithelial mesenchymal transition. Ecancermedicalscience 14:1099","journal-title":"Ecancermedicalscience"},{"key":"8087_CR6","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 68:394\u20134246","journal-title":"CA"},{"key":"8087_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316674875","author":"JS Mishra","year":"2016","unstructured":"Mishra JS, Hankins GD, Kumar S (2016) Testosterone downregulates angiotensin II type-2 receptor via androgen receptor-mediated ERK1\/2 MAP kinase pathway in rat aorta. J Renin Angiotensin Aldosterone Syst. https:\/\/doi.org\/10.1177\/1470320316674875","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"2","key":"8087_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.urolonc.2019.02.010","volume":"38","author":"C Melloni","year":"2020","unstructured":"Melloni C, Roe MT (2020) Androgen deprivation therapy and cardiovascular disease. Urol Oncol 38(2):45\u201352","journal-title":"Urol Oncol"},{"issue":"1","key":"8087_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s42003-020-1088-9","volume":"3","author":"D Chakravarty","year":"2020","unstructured":"Chakravarty D et al (2020) Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun Biol 3(1):374","journal-title":"Commun Biol"},{"issue":"8","key":"8087_CR10","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.annonc.2020.04.479","volume":"31","author":"M Montopoli","year":"2020","unstructured":"Montopoli M et al (2020) Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol 31(8):1040\u20131045","journal-title":"Ann Oncol"},{"issue":"11","key":"8087_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"AJ George","year":"2010","unstructured":"George AJ, Thomas WG, Hannan RD (2010) The renin\u2013angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10(11):745\u2013759","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"8087_CR12","first-page":"1139","volume":"2","author":"H Uemura","year":"2003","unstructured":"Uemura H et al (2003) Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2(11):1139\u20131147","journal-title":"Mol Cancer Ther"},{"key":"8087_CR13","first-page":"99","volume-title":"Regulation of angiogenesis by angiotensin II","author":"J Haendeler","year":"2004","unstructured":"Haendeler J, Dimmeler S, Unger T, Sch\u00f6lkens BA (2004) Regulation of angiogenesis by angiotensin II, vol I. Springer, Berlin Heidelberg: Berlin, Heidelberg, pp 99\u2013109"},{"issue":"2","key":"8087_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.peptides.2012.07.022","volume":"37","author":"K Domi\u0144ska","year":"2012","unstructured":"Domi\u0144ska K et al (2012) Similarities and differences between effects of angiotensin III and angiotensin II on human prostate cancer cell migration and proliferation. Peptides 37(2):200\u2013206","journal-title":"Peptides"},{"key":"8087_CR15","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan VP et al (2013) Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 4:2516","journal-title":"Nat Commun"},{"issue":"1","key":"8087_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13046-019-1127-x","volume":"38","author":"Q Zhang","year":"2019","unstructured":"Zhang Q et al (2019) Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress. J Exp Clin Cancer Res 38(1):116","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"8087_CR17","doi-asserted-by":"publisher","first-page":"e0234269","DOI":"10.1371\/journal.pone.0234269","volume":"15","author":"A Siltari","year":"2020","unstructured":"Siltari A et al (2020) Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS ONE 15(6):e0234269","journal-title":"PLoS ONE"},{"issue":"3","key":"8087_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10238-020-00622-7","volume":"20","author":"L Smith","year":"2020","unstructured":"Smith L et al (2020) Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults. Clin Exp Med 20(3):409\u2013416","journal-title":"Clin Exp Med"},{"issue":"6","key":"8087_CR19","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3892\/ijo.2016.3458","volume":"48","author":"K Domi\u0144ska","year":"2016","unstructured":"Domi\u0144ska K et al (2016) Interaction between angiotensin II and relaxin 2 in the progress of growth and spread of prostate cancer cells. Int J Oncol 48(6):2619\u20132628","journal-title":"Int J Oncol"},{"issue":"4","key":"8087_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/HYPERTENSIONAHA.106.076216","volume":"50","author":"MC Chappell","year":"2007","unstructured":"Chappell MC (2007) Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1\u20137)-MAS receptor axis: more than regulation of blood pressure? Hypertension 50(4):596\u2013599","journal-title":"Hypertension"},{"issue":"7","key":"8087_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/CS20110036","volume":"121","author":"S Bosnyak","year":"2011","unstructured":"Bosnyak S et al (2011) Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 121(7):297\u2013303","journal-title":"Clin Sci (Lond)"},{"issue":"7","key":"8087_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","volume":"11","author":"F Jiang","year":"2014","unstructured":"Jiang F et al (2014) Angiotensin-converting enzyme 2 and angiotensin 1\u20137: novel therapeutic targets. Nat Rev Cardiol 11(7):413\u2013426","journal-title":"Nat Rev Cardiol"},{"key":"8087_CR23","doi-asserted-by":"crossref","unstructured":"Tetzner A et al (2016) G-protein-coupled receptor MrgD is a receptor for angiotensin-(1\u20137) involving adenylyl cyclase, cAMP, and phosphokinase. Hypertension, 68(1), 185","DOI":"10.1161\/HYPERTENSIONAHA.116.07572"},{"issue":"12","key":"8087_CR24","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1097\/HJH.0b013e3282f0143c","volume":"25","author":"C Peir\u00f3","year":"2007","unstructured":"Peir\u00f3 C et al (2007) Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor mas: a new target to improve endothelial function. J Hypertens 25(12):2421\u20132425","journal-title":"J Hypertens"},{"issue":"19","key":"8087_CR25","doi-asserted-by":"publisher","first-page":"11867","DOI":"10.1074\/jbc.273.19.11867","volume":"273","author":"T Walther","year":"1998","unstructured":"Walther T et al (1998) Sustained long term potentiation and anxiety in mice lacking the mas protooncogene. J Biol Chem 273(19):11867\u201311873","journal-title":"J Biol Chem"},{"issue":"1","key":"8087_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcp.22209","volume":"225","author":"Y Zhao","year":"2010","unstructured":"Zhao Y et al (2010) Angiotensin II\/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase\/Akt pathway. J Cell Physiol 225(1):168\u2013173","journal-title":"J Cell Physiol"},{"issue":"1","key":"8087_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/1470320311426023","volume":"13","author":"S Bernardi","year":"2012","unstructured":"Bernardi S et al (2012) Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. J Renin Angiotensin Aldosterone Syst 13(1):202\u2013209","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"4","key":"8087_CR28","first-page":"941","volume":"23","author":"Y Feng","year":"2010","unstructured":"Feng Y et al (2010) The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep 23(4):941\u2013948","journal-title":"Oncol Rep"},{"issue":"1","key":"8087_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2011.03.011","volume":"307","author":"L Zhou","year":"2011","unstructured":"Zhou L et al (2011) Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Cancer Lett 307(1):18\u201325","journal-title":"Cancer Lett"},{"issue":"1","key":"8087_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/pros.22542","volume":"73","author":"B Krishnan","year":"2013","unstructured":"Krishnan B et al (2013) Angiotensin-(1\u20137) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate 73(1):71\u201382","journal-title":"Prostate"},{"issue":"2","key":"8087_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.bbrc.2015.03.035","volume":"460","author":"S Zheng","year":"2015","unstructured":"Zheng S et al (2015) Ang-(1\u20137) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. Biochem Biophys Res Commun 460(2):333\u2013340","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"8087_CR32","doi-asserted-by":"publisher","first-page":"F585","DOI":"10.1152\/ajprenal.00538.2009","volume":"299","author":"WC Burns","year":"2010","unstructured":"Burns WC et al (2010) Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1\u20137\/MAS-1-dependent pathways. Am J Physiol Renal Physiol 299(3):F585\u2013F593","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"8087_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbrc.2015.02.030","volume":"459","author":"G Ye","year":"2015","unstructured":"Ye G et al (2015) The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma. Biochem Biophys Res Commun 459(1):18\u201323","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"8087_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.canlet.2016.04.006","volume":"376","author":"C Yu","year":"2016","unstructured":"Yu C et al (2016) Downregulation of ACE2\/Ang-(1\u20137)\/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry. Cancer Lett 376(2):268\u2013277","journal-title":"Cancer Lett"},{"issue":"2","key":"8087_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1620\/tjem.217.123","volume":"217","author":"L Zhou","year":"2009","unstructured":"Zhou L et al (2009) Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. Tohoku J Exp Med 217(2):123\u2013131","journal-title":"Tohoku J Exp Med"},{"issue":"7","key":"8087_CR36","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1007\/s13277-015-3171-2","volume":"36","author":"H Zong","year":"2015","unstructured":"Zong H et al (2015) Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer. Tumour Biol 36(7):5171\u20135177","journal-title":"Tumour Biol"},{"issue":"1","key":"8087_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13046-019-1156-5","volume":"38","author":"Q Zhang","year":"2019","unstructured":"Zhang Q et al (2019) ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa\/VEGFR2\/ERK pathway. J Experimental Clin Cancer Res 38(1):173","journal-title":"J Experimental Clin Cancer Res"},{"issue":"577","key":"8087_CR38","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1126\/scitranslmed.abc0170","volume":"13","author":"P Khanna","year":"2021","unstructured":"Khanna P et al (2021) ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1\u20137) as a therapy for clear cell renal cell carcinoma. Sci Transl Med 13(577):170","journal-title":"Sci Transl Med"},{"issue":"9","key":"8087_CR39","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/cas.12719","volume":"106","author":"Y Luo","year":"2015","unstructured":"Luo Y et al (2015) Expression of MAS1 in breast cancer. Cancer Sci 106(9):1240\u20131248","journal-title":"Cancer Sci"},{"issue":"4","key":"8087_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3892\/ol.2021.12568","volume":"21","author":"F L\u00e4ssig","year":"2021","unstructured":"L\u00e4ssig F et al (2021) Expression of canonical transient receptor potential channels in U-2 OS and MNNG-HOS osteosarcoma cell lines. Oncol Lett 21(4):307","journal-title":"Oncol Lett"},{"issue":"21","key":"8087_CR41","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.2174\/0929867321666140205133357","volume":"21","author":"PE Gallagher","year":"2014","unstructured":"Gallagher PE et al (2014) Angiotensin-(1\u20137): a peptide hormone with anti-cancer activity. Curr Med Chem 21(21):2417\u20132423","journal-title":"Curr Med Chem"},{"issue":"1","key":"8087_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/pros.22540","volume":"73","author":"B Krishnan","year":"2013","unstructured":"Krishnan B et al (2013) Angiotensin-(1\u20137) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate 73(1):60\u201370","journal-title":"Prostate"},{"issue":"4","key":"8087_CR43","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1158\/0008-5472.CAN-18-1207","volume":"79","author":"KT Murphy","year":"2019","unstructured":"Murphy KT et al (2019) Mas receptor activation slows tumor growth and attenuates muscle wasting in cancer. Cancer Res 79(4):706\u2013719","journal-title":"Cancer Res"},{"issue":"6","key":"8087_CR44","doi-asserted-by":"publisher","first-page":"e38618","DOI":"10.1371\/journal.pone.0038618","volume":"7","author":"S Nishimura","year":"2012","unstructured":"Nishimura S et al (2012) MRGD, a MAS-related G-protein coupled receptor, promotes tumorigenisis and is highly expressed in lung cancer. PLoS ONE 7(6):e38618","journal-title":"PLoS ONE"},{"issue":"6","key":"8087_CR45","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/1535-7163.MCT-09-0161","volume":"8","author":"DR Soto-Pantoja","year":"2009","unstructured":"Soto-Pantoja DR et al (2009) Angiotensin-(1\u20137) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 8(6):1676\u20131683","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"8087_CR46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.18632\/oncotarget.13396","volume":"8","author":"X Chen","year":"2017","unstructured":"Chen X et al (2017) AAV-Mediated angiotensin 1\u20137 overexpression inhibits tumor growth of lung cancer in vitro and in vivo. Oncotarget 8(1):354\u2013363","journal-title":"Oncotarget"},{"issue":"1","key":"8087_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/1535-7163.MCT-14-0981","volume":"15","author":"N Pei","year":"2016","unstructured":"Pei N et al (2016) Angiotensin-(1\u20137) decreases cell growth and angiogenesis of human nasopharyngeal carcinoma xenografts. Mol Cancer Ther 15(1):37\u201347","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"8087_CR48","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00109-018-1704-z","volume":"96","author":"YT Lin","year":"2018","unstructured":"Lin YT et al (2018) Pre-treatment with angiotensin-(1\u20137) inhibits tumor growth via autophagy by downregulating PI3K\/Akt\/mTOR signaling in human nasopharyngeal carcinoma xenografts. J Mol Med (Berl) 96(12):1407\u20131418","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"8087_CR49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bbrc.2018.05.138","volume":"502","author":"K Domi\u0144ska","year":"2018","unstructured":"Domi\u0144ska K et al (2018) Influence and mechanism of Angiotensin 1\u20137 on biological properties of normal prostate epithelial cells. Biochem Biophys Res Commun 502(1):152\u2013159","journal-title":"Biochem Biophys Res Commun"},{"issue":"17","key":"8087_CR50","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.3390\/ijms21176227","volume":"21","author":"K Domi\u0144ska","year":"2020","unstructured":"Domi\u0144ska K et al (2020) The impact of Ang-(1\u20139) and Ang-(3\u20137) on the biological properties of prostate cancer cells by modulation of inflammatory and steroidogenesis pathway genes. Int J Mol Sci 21(17):6227","journal-title":"Int J Mol Sci"},{"issue":"10","key":"8087_CR51","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.annonc.2020.06.005","volume":"31","author":"O Caffo","year":"2020","unstructured":"Caffo O et al (2020) On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. Ann Oncol 31(10):1415\u20131416","journal-title":"Ann Oncol"},{"key":"8087_CR52","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/andr.12821","volume":"9","author":"G Rastrelli","year":"2020","unstructured":"Rastrelli G et al (2020) Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology 9:88\u201398","journal-title":"Andrology"},{"issue":"10","key":"8087_CR53","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.purol.2020.05.007","volume":"30","author":"G Mjaess","year":"2020","unstructured":"Mjaess G et al (2020) COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. Prog Urol 30(10):484\u2013487","journal-title":"Prog Urol"},{"key":"8087_CR54","doi-asserted-by":"publisher","first-page":"117905","DOI":"10.1016\/j.lfs.2020.117905","volume":"256","author":"N Banu","year":"2020","unstructured":"Banu N et al (2020) Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to macrophage activation syndrome: therapeutic implications. Life Sci 256:117905","journal-title":"Life Sci"},{"issue":"6965","key":"8087_CR55","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426(6965):450\u2013454","journal-title":"Nature"},{"issue":"6","key":"8087_CR56","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/cells9061336","volume":"9","author":"F Acconcia","year":"2020","unstructured":"Acconcia F (2020) The network of angiotensin receptors in breast cancer. Cells 9(6):1336","journal-title":"Cells"},{"issue":"S1","key":"8087_CR57","first-page":"1","volume":"34","author":"R Feldman","year":"2020","unstructured":"Feldman R et al (2020) Aldosterone mediates a mineralocorticoid receptor-mediated increase in prostate cancer cell migration. FASEB J 34(S1):1\u20131","journal-title":"FASEB J"},{"issue":"6","key":"8087_CR58","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/17843286.2018.1543827","volume":"74","author":"B Dhondt","year":"2019","unstructured":"Dhondt B et al (2019) Abiraterone and spironolactone in prostate cancer: a combination to avoid. Acta Clin Belg 74(6):439\u2013444","journal-title":"Acta Clin Belg"},{"issue":"5","key":"8087_CR59","first-page":"1117","volume":"57","author":"J Ishida","year":"1999","unstructured":"Ishida J, Fukamizu A (1999) Angiotensin II and apoptosis. Nihon Rinsho 57(5):1117\u20131123","journal-title":"Nihon Rinsho"},{"issue":"6","key":"8087_CR60","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00120-020-01187-9","volume":"59","author":"G von Amsberg","year":"2020","unstructured":"von Amsberg G, Merseburger AS (2020) Treatment of metastatic, castration-resistant prostate cancer. Urologe A 59(6):673\u2013679","journal-title":"Urologe A"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-08087-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-08087-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-08087-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T13:55:27Z","timestamp":1675346127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-08087-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["8087"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-08087-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"assertion":[{"value":"20 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fabian Sehn, Hartwig B\u00fcttner: Part-time employee of Takeda; the present publication has been prepared independently and outside of the employment; the employer is not involved in any of subjects dealt with in this publication and did not provide any form of support.\u00a0Sven Perner: Consultant: Ventana Medical\nSystems, Roche, Novartis, Astellas, Bristol-Myers Squibb, MetaSystems, Merck\nSerono, MSD. Research: Ventana Medical Systems, Roche, Bristol-Myers Squibb,\nMSD, Boehringer-Ingelheim. Lectures\/Speaker\/Honoraria: Ventana Medical Systems,\nRoche, Novartis, Astellas, Bristol-Myers Squibb, MetaSystems, Merck Serono,\nMSD. Mario W. Kramer: Honoraria\/Consultation: Bayer, BMS, Eusai, Novartis,\nMerck, MSD, Pfizer, Roche. Travel Grants: Ipsen, Janssen, Merck, Novartis. Axel\nS. Merseburger: Lectures\/Speaker\/Honoraria: AstraZeneca,\nBristol-Myers Squibb, Eisai, Ipsen, MSD, Merck Serono, Janssen, Takeda, TEVA,\nAstellas, Novartis, Pfizer und Roche. Consultant: AstraZeneca, Astellas,\nBristol-Myers Squibb, Ipsen, Janssen, EUSAPharm, MSD, Merck Serono, Novartis,\nTakeda, Teva, Pfizer und Roche. Research and clinical trials: AstraZeneca,\nAstellas, Bristol-Myers Squibb, Ipsen, Janssen, EUSAPharm, MSD, Merck Serono,\nNovartis, Takeda, Teva, Pfizer und Roche. Marie C. Roesch: Lectures\/Honoraria\/Travel Grants:\nIpsen, Novartis, Sanofi, Solution Akademie. Beate Godau, Marten M\u00fcller, Semih Sarcan , Anne\nOffermann declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No human nor animal subjects have been involved in the presented publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and\/or participants"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}